EUCTR2005-004268-21-HUActive, not recruitingNot Applicable
A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in type 2 diabetic patients from studies BM18248 or BM18249.
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- F. Hoffmann-La Roche Ltd
- Enrollment
- 370
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Type 2 diabetic patients who have completed phase 2 studies BM18248 or BM18249; OR who have discontinued participation due to hypoglycemia as per protocols
- •Patients able and willing to give written informed consent and to comply with the requirements of the present protocol
- •Patients considered by the investigator as suitable for long term treatment with RO4389620 with regards to compliance and risk assessment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •- Significant coronary events, e.g., unstable angina, myocardial infarction within the past 3 months
- •- Congestive heart failure requiring pharmacologic therapy in patients taking metformin
- •- Transient ischemic attacks, or cerebrovascular accident within the past 3 months
- •- Significant chronic illness, e.g., respiratory insufficiency, active malignant diseases, major active infection, or unstable mental disorders
- •- Uncontrolled hypertension (SBP > 160 mmHg and/or DBP > 100 mmHg, with or without treatment)
- •- Concomitant use of systemic treatment with strong CYP450 3A4 inducers (such as rifampicin), or potent CYP450 3A4 inhibitors (such as atanazavir, indinavir, nelfinavir, ritonavir, saquinavir, itraconazole, ketoconazole, voriconazole nefazodone, telithromycin or clarithromycin)
- •- Impaired liver function (ALT, AST, total and direct bilirubin or Alk. phosphatase > 2.5 x ULN) at the end-of-treatment (ET) or premature withdrawal (PW) assessment in BM18248 or BM18249
- •- Serum creatinine > 2.0 mg/dl [177 µmol/L] (Patients taking metformin with a creatinine equal or more than 1.5 mg/dl in man and equal or morel than 1.4 mg/dl in woman) at the ET or PW assessment in BM18248 or BM18249
- •- Any abnormality in clinical laboratory tests or ECG, which precludes their safe involvement in the study as judged by the investigator
- •- Pregnant or lactating women
- •- Women of child bearing potential who, with their partners refuse to use two forms of contraception (including one barrier method) during the treatment and follow-up periods
- •- Alcohol or drug abuse
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in type 2 diabetic patients from studies BM18248 or BM18249.EUCTR2005-004268-21-DEF. Hoffmann-La Roche Ltd370
Active, not recruiting
Not Applicable
A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in type 2 diabetic patients from studies BM18248 or BM18249.Type 2 diabetes MellitusMedDRA version: 7Level: lowClassification code 10012613EUCTR2005-004268-21-GBF. Hoffmann-La Roche Ltd370
Active, not recruiting
Phase 3
A study to evaluate the long-term safety and tolerability of faricimab administered in patients previously enrolled in Roche-sponsored studiesMacular degenerationISRCTN14123846F. Hoffman-la Roche350
Active, not recruiting
Not Applicable
An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803.EUCTR2004-000047-18-SEBiogen Idec Ltd.1,900
Active, not recruiting
Phase 1
A study designed to determine safety and efficacy of Daclizumab HighYield Process (DAC HYP) in patients with Multiple Sclerosis Who HaveCompleted Treatment in a previous study, 205MS202 (SELECTION)Relapsing-remitting Multiple SclerosisMedDRA version: 19.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-015318-23-DEBiogen Idec Ltd.450